Another domestic and international phase I/II study demonstrated that the optimal ORR reached 77.8% when treating advanced NSCLC with EGFR ex20ins using first-line single-agent RP2D dosing (300 mg QD) of sunvozertinib (85). Here, EGFR is linked to non-small cell lung carcinoma.